Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

Dow Jones

02/10

2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. "Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term," Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 09, 2026 17:19 ET (22:19 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610721661"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610721661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610721661?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610721661","market":"us","top_or_hot":-1,"title":"Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 06:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610721661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610721661","pubTimestamp":1770675540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD"},"translate_title":"Pro Medicus的商业案例因人工智能的采用而更具吸引力——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 17:19 ET (22:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}